Caribou Biosciences, Inc. (CRBU) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 9 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CRBU is $7.00, representing a +230.2% upside from the current price of $2.12. Price targets range from a low of $7.00 to a high of $7.00.